Skip to main content
SpringerLink
Log in

Relapsed/refractory AML has high cost burden in USA

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2016 US dollars

Reference

  • Pandya BJ, et al. Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database. Advances in Therapy : 20 Jun 2019. Available from: URL: http://doi.org/10.1007/s12325-019-01003-7

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Relapsed/refractory AML has high cost burden in USA. PharmacoEcon Outcomes News 831, 28 (2019). https://doi.org/10.1007/s40274-019-6016-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-6016-1

Search

Navigation